COVID-19 vaccine effectiveness
(Randomized evidence)
If you want to see all comparisons, please click here
BioNTech/Fosun Pharma/Pfizer - BNT162b2 vs Placebo
You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.
Forest plots
(last update: 2021-06-18)
Trial subgroup analysis
(last update: 2021-01-18)
Summary of findings
2021-06-24
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT04368728 Pfizer/BioNTech + Fosun Pharma Frenck R, N Engl J Med, 2021 Full text Commentary |
RNA based vaccine |
BNT162b2 |
Placebo |
RCTPhase 3 | Adolescents aged 12 to 15 years with no previous Covid-19 diagnosis or SARS-CoV-2 infection in 29 centers in the USA | N=2264 |
Some concerns Details |
|
|
NCT04368728 Pfizer/BioNTech + Fosun Pharma Polack F, N Engl J Med, 2020 Full text Commentary ; Commentary ; Commentary ; Commentary ; Commentary |
RNA based vaccine |
BNT162b2 |
Placebo |
RCTPhase 2/3 | Healthy SARS-CoV-2 DNA negative adults in multiple centres in Argentina, Brazil, Germany, South Africa, Turkey, and the USA | N=43448 |
Some concerns Details |
|
|
NCT04368728 BioNTech SE, Pfizer Walsh E, N Engl J Med, 2020 Full text Commentary |
RNA based vaccine |
BNT162b1 10 mcg D1/21 BNT162b1 20 mcg D1/21 BNT162b1 30 mcg D1/21 BNT162b1 100 mcg D1/21 BNT162b2 10 mcg D1/21 BNT162b2 20 mcg D1/21 BNT162b2 30 mcg D1/21 |
BNT162b1 30 mcg D1/21 |
RCTPhase 1 | Healthy SARS-CoV-2 serology/DNA negative adults in four centres in USA | N=195 |
Low Details |
|
|
NCT04523571 ; ChiCTR BioNTech / Pfizer / Fosun Pharma Zhu F, ResearchSquare, 2021 Full text Commentary ; Commentary |
RNA based vaccine |
BNT126b1 10 mcg/0.5 ml 2- BNT126b1 30 mcg/0.5 ml 2- |
Placebo |
RCTPhase 1 | Healthy SARS-CoV-2 infection-free adults aged 18-55 and 65-85 at a single center in China | N=144 |
Some concerns Details |
|